Paper published in a journal (Scientific congresses and symposiums)
Cessation of nucleos(t)ide analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
Van Hees, S; Bourgeois, S; Van Vlierberghe, H et al.
2017In Hepatology, 66 (S1), p. 934
Peer Reviewed verified by ORBi
 

Files


Full Text
poster AASLD 2017.pdf
Publisher postprint (89.41 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Hees, S
Bourgeois, S
Van Vlierberghe, H
Sersté, T
Francque, S
Michielsen, P
Sprengers, D
Reynaert, H
Henrion, J
Negrin Dastis, S
DELWAIDE, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Lasser, L
Decaestecker, J
Orlent, H
Janssens, F
Robaeys, G
Colle, I
Starkel, P
Moreno, C
Nevens, F
Vanwolleghem, T
More authors (11 more) Less
Language :
English
Title :
Cessation of nucleos(t)ide analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
Publication date :
October 2017
Event name :
Liver Meeting American Association for the Study of Liver Diseases
Event place :
Washington, United States
Event date :
du 20 octobre 2017 au 24 octobre 2017
Audience :
International
Journal title :
Hepatology
ISSN :
0270-9139
eISSN :
1527-3350
Publisher :
Wiley, Hoboken, United States - New Jersey
Volume :
66
Issue :
S1
Pages :
A934
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 November 2017

Statistics


Number of views
44 (1 by ULiège)
Number of downloads
120 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi